Find

Find Therapeutics Announces Appointment of Dr. Anthony Johnson to its Board of Directors

Retrieved on: 
Monday, March 4, 2024

"On behalf of the Board of Directors, I am delighted to welcome Tony to the team," said Philippe Douville, President and CEO of Find Therapeutics.

Key Points: 
  • "On behalf of the Board of Directors, I am delighted to welcome Tony to the team," said Philippe Douville, President and CEO of Find Therapeutics.
  • He currently serves as President and CEO of Domain Therapeutics, Chairman of the Board for Outrun Therapeutics and Board Director for Nanosyrinx.
  • Dr. Johnson was previously President and CEO of Goldfinch Bio and, prior to that, Head of Early Clinical Development.
  • Find Therapeutics also announces that Pascal Neuville, Ph.D., has stepped down from the board as a Non-Executive Director effective March 3, 2024.

Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon

Retrieved on: 
Friday, March 1, 2024

MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.

Key Points: 
  • First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence
    MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.
  • ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.
  • Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9029352-boston-scientific-fda-ap...
    "With more than 100,000 patients treated globally to date in both clinical and commercial settings, we are very pleased to introduce this proven therapy as the first drug-coated coronary balloon in the U.S," said Lance Bates, president, Interventional Cardiology Therapies, Boston Scientific.
  • Boston Scientific plans to launch the technology in the U.S. in the coming months.

Treat Your "Sole" and "Sole-mate" This Valentine's Day with Kerasal®

Retrieved on: 
Wednesday, February 14, 2024

This Valentine's Day and every day after, pamper yourself and your loved ones with the at-home 'spa foot vacation' that will leave your feet extra attractive and silky-smooth, guaranteed to make that special Valentine's Day– and night– much more enjoyable.

Key Points: 
  • This Valentine's Day and every day after, pamper yourself and your loved ones with the at-home 'spa foot vacation' that will leave your feet extra attractive and silky-smooth, guaranteed to make that special Valentine's Day– and night– much more enjoyable.
  • "During these cold winter months, struggling with dry and cracked feet is very common," says Whitney Kopp, Kerasal Brand Lead.
  • Treat yourself and your loved ones to a Valentine's Day experience that even Cupid himself could not resist!
  • The Find Your "Sole-mate" Kerasal Valentine's Day Collection includes:
    Kerasal® Intensive Foot Repair™ Ointment offers visible results in just 1 day.

Scientific Systems Conducts Live Fully Autonomous Multi-Vehicle Defensive Counter Air Missions

Retrieved on: 
Tuesday, January 16, 2024

WOBURN, Mass., Jan. 16, 2024 /PRNewswire/ -- Scientific Systems Company, Inc. (SSCI) successfully flew multiple flight tests of its Collaborative Mission Autonomy (CMA) software running on a live General Atomics Aeronautical Systems, Inc. (GA-ASI) MQ-20 Avenger® Unmanned Combat Air Vehicle. In these November 2023 flight tests, CMA software commanded a mixed team of Live, Virtual, and Constructive (LVC) MQ-20 platforms to execute a fully autonomous multi-vehicle Defensive Counter Air mission.

Key Points: 
  • In these November 2023 flight tests, CMA software commanded a mixed team of Live, Virtual, and Constructive (LVC) MQ-20 platforms to execute a fully autonomous multi-vehicle Defensive Counter Air mission.
  • Scientific Systems' software was embedded onboard all the live, virtual, and constructive MQ-20 platforms, successfully managing the autonomous mission at the edge to compensate for communication and coordination challenges.
  • Scientific Systems' algorithms use operator pre-mission inputs to generate tailored, coordinated flight behaviors that address mission objectives by optimizing aircraft positioning, engagement parameters, and defensive maneuvers.
  • Earlier Scientific Systems test flight programs have successfully demonstrated a variety of air-to-ground, and ground support missions.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kenvue, Inc. of Class Action Lawsuit and Upcoming Deadline – KVUE

Retrieved on: 
Monday, December 4, 2023

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.

Key Points: 
  • NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kenvue, Inc. of Class Action Lawsuit and Upcoming Deadline – KVUE

Retrieved on: 
Tuesday, November 21, 2023

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.

Key Points: 
  • NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

FP Canada™ launches new consumer website aimed at increasing access to professional financial planning for all Canadians

Retrieved on: 
Thursday, November 23, 2023

The relaunched website is a hub for helpful resources on the value of having a financial plan and working with a Certified Financial Planner® professional or Qualified Associate Financial Planner™ professional.

Key Points: 
  • The relaunched website is a hub for helpful resources on the value of having a financial plan and working with a Certified Financial Planner® professional or Qualified Associate Financial Planner™ professional.
  • The site enables consumers to more easily connect with professional financial planners who meet their unique needs via FP Canada's redesigned Find Your Planner tool.
  • The new website aims to ease the stress Canadians harbour about money by ensuring they can easily and seamlessly access professional financial planning that supports their diverse needs.
  • Visit the website to learn more about the benefits of financial planning services and working with a CFP professional or QAFP professional.

OPPO Find N3 Series Officially Launched, Redefining the Smartphone Landscape

Retrieved on: 
Friday, November 17, 2023

This series includes the Find N3 and Find N3 Flip, both delivering breakthrough experiences across imaging, design, and usability.

Key Points: 
  • This series includes the Find N3 and Find N3 Flip, both delivering breakthrough experiences across imaging, design, and usability.
  • This commitment is reflected in the exclusive benefits offered through the OPPO Premium Service, designed to provide hassle-free support to OPPO Find N3 series' users.
  • The eagerly anticipated Find N3 series from OPPO is available for pre-order on OPPO's websites and partner retail stores, with official sales commencing on 23rd November.
  • The Find N3 is priced at Dhs7,999, while the Find N3 Flip comes at a price of Dhs3,999.

OPPO Find N3 Series Officially Launched, Redefining the Smartphone Landscape

Retrieved on: 
Friday, November 17, 2023

This series includes the Find N3 and Find N3 Flip, both delivering breakthrough experiences across imaging, design, and usability.

Key Points: 
  • This series includes the Find N3 and Find N3 Flip, both delivering breakthrough experiences across imaging, design, and usability.
  • This commitment is reflected in the exclusive benefits offered through the OPPO Premium Service, designed to provide hassle-free support to OPPO Find N3 series' users.
  • The eagerly anticipated Find N3 series from OPPO is available for pre-order on OPPO's websites and partner retail stores, with official sales commencing on 23rd November.
  • The Find N3 is priced at Dhs7,999, while the Find N3 Flip comes at a price of Dhs3,999.

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

Retrieved on: 
Friday, November 3, 2023

"Using the novel IMC technology to conduct further translational data analysis from the AWARE-1 study in early-stage breast cancer patients has confirmed and expanded our understanding of pelareorep's mechanism of action in the tumor microenvironment," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics.

Key Points: 
  • "Using the novel IMC technology to conduct further translational data analysis from the AWARE-1 study in early-stage breast cancer patients has confirmed and expanded our understanding of pelareorep's mechanism of action in the tumor microenvironment," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics.
  • "We look forward to incorporating these important translational learnings into our registrational program for HR+/HER2- metastatic breast cancer.
  • These findings likely also have implications for other indications where we have seen signals of efficacy with atezolizumab/pelareorep combinations, including pancreatic cancer in the GOBLET study focused on gastrointestinal cancers."
  • This supports pelareorep's ability to modify the tumor microenvironment and enhance the responsiveness of cancers to checkpoint inhibitor therapy."